SLC5A2 and Hypoglycemia: Both SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been proven to reduce major adverse cardiovascular events with little risk of hypoglycemia (Bertoccini and Baroni, 2021).